Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The CAMS-COI Joint webinar entitled “COVID Without Borders-A collaboration to Investigate A New Disease III – Diagnostic and Treatment for COVID-19” was held online on the morning of November 17th 2020.

On behalf of COI, Professor Tao Dong hosted this webinar and introduced two distinguished guests, Professor Chengyu Jiang and Professor Alain Townsend. 

The first speaker was Professor Chengyu Jiang from Chinese Academy of Medical Sciences, who is Deputy Director of Institute of Basic Medicine and Professor of Peking Union Medical College. She reported on her work entitled “Repurposing Drugs and Traditional Chinese Medicine—Treatments for COVID-19”. In her talk, she introduced the methodology of drug repurposing, the recommended repurposing drugs based on the role of renin angiotensin system in COVID-19 induced ARDS and the novel form of medicine--herbal decoctosome from traditional Chinese medicine as effective drugs for COVID-19 treatment. 


Screenshot of the online seminar COVID Without Borders- A collaboration to Investigate A New Disease III – Vaccine Research and Development


The second speaker was Professor Alain Townsend, who is an immunologist and Professor of Molecular Immunology in University of Oxford, Fellow of the Royal Society (FRS) and Fellow of Royal College of Physicians (FRCP).

Professor Townsend brought us the talk “Three COVID-19 Projects: Rapid Affordable Antibody Diagnostic, SpyCatcher-RBD Based Vaccine and Isolation of Neutralising Antibodies”. Professor Townsend introduced in detail the methodology of haemagglutination based antibody diagnostic test, isolation of neutralizing mAbs from SARS-CoV-2 infected convalescent patients, as well as the research on a sub-unit vaccine for COVID-19 that does not require a cold-chain and can be produced rapidly and cheaply.  


Screenshot of the online seminar COVID Without Borders- A collaboration to Investigate A New Disease III – Vaccine Research and Development


In the subsequent Q&A session, the three professors had a lively and pertinent discussion on the protection of the vaccine, the immune escape resulted from the virus mutation, the application prospects and timeline of candidate neutralizing antibodies, and the choice of therapeutic strategies.

At last, Professor Tao Dong expressed her gratitude to both speakers for their fascinating speeches and insightful discussions, and audience for taking time to participate. Our next session will be in early 2021.

Similar stories

COVID-19 Impact Report

To date, the CAMS-Oxford Institute (COI) has funded 11 COVID-19 projects aiming to understand immune responses to COVID-19, contributing 18 published research articles to the field. Read about the impact the COI has had on our understanding of COVID-19 pathology and immunology.

CAMS-Oxford Joint Symposium: Population Medicine & Public Health

On 12th December 2022, the Chinese Academy of Medical Sciences-Oxford University Joint Symposium on ‘Population Medicine & Public Health’ was held online.

Strong cytotoxic T cell responses to an internal viral component are associated with mild COVID-19 disease

Study from the Dong Group reveals key differences in the adaptive immune responses of patients with mild vs. severe COVID-19, highlighting a potential new vaccine target.

CAMS-Oxford Joint Symposium: Clinical Medicine Research Without Borders

On the morning of 29th June 2021, the symposium “CAMS Oxford Joint Symposium- Clinical Medicine Research Without Borders” was held online, jointly organized by the Chinese Academy of Medical Sciences (CAMS) and CAMS-Oxford Institute (COI), and was attended by 1300 participants including Principal Investigators, researchers and students from Oxford and CAMS.

Oxford University breakthrough on global COVID-19 vaccine

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

COVID Without Borders: Vaccine Research and Development

The webinar entitled “COVID Without Borders: A collaboration to Investigate a New Disease II - Vaccine Research and Development” was held online on 22nd September 2020.